drugset / Trial / NCT06878976
Open-Label Safety Study of Solriamfetol in Subjects With Binge Eating Disorder
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 3, multi-center, open-label study to evaluate the long-term safety and efficacy of solriamfetol in the treatment of binge eating disorder (BED) in adults.
Timeline
- Start
- 2025-02-20
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Solriamfetol | Small molecule | 75 mg | — |
| Subject | Solriamfetol | Small molecule | 150 mg | — |
| Subject | Solriamfetol | Small molecule | 300 mg | — |